Association Between Topical Calcineurin Inhibitor Use and Ke
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Topical calcineurin inhibitors (TCIs), primarily used to treat atopic dermatitis (AD), carry a black box label warning users about the potential for increased skin cancer risk. The risk associated with keratinocyte carcinoma (KC), the most common cancer, defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), remains poorly defined because findings from large-scale postmarketing surveillance studies have not been reported.

To examine KC risk overall and by subtype (BCC and SCC) among adults with AD exposed to TCIs compared with those exposed to topical corticosteroids (primary comparator group) and those unexposed to TCIs or topical corticosteroids (alternative comparator group) as well as alterations in risk with TCI dose, frequency, and duration of exposure a retrospective cohort study was conducted of adults 40 years or older (n =93746) with a physician-rendered diagnosis of AD or dermatitis.

Time-varying pharmacy-dispensed TCI exposure (n = 7033) over the study period was compared with topical corticosteroids (n = 73674) and no TCI or topical corticosteroid exposure (n = 46141). Among a cohort of 93746 members, the mean (SD) age was 58.5 years, and 55 023 patients were women. Multivariable Cox proportional hazards regression revealed no association between TCI exposure and KC risk compared with topical corticosteroid exposure. Similarly, there were no significant differences in BCC risk or SCC risk. Changing the comparator group to unexposed individuals yielded similar findings. There were no associations between TCI dose, frequency, and duration of use and BCC, SCC, or overall KC risk.

The results of this postmarketing surveillance study of adult health plan members with AD revealed no apparent association between TCI exposure and overall KC, BCC, or SCC risk. Secondary analyses examining dose, frequency, and duration of TCI exposure revealed no associations. These findings suggest that use of TCIs may be safe with respect to KC risk among adults with AD.

source: https://jamanetwork.com/journals/jamadermatology/fullarticle/2768937
Like
Comment
Share